European Patent granted for Intercell's synthetic adjuvant IC31TM

02-May-2006

Intercell announced that the European Patent Office has granted an additional key patent covering a component of Intercell's novel proprietary synthetic adjuvant IC31TM. The newly issued patent (EP 1 326 634 B) specifically covers the peptide (KLK) component of IC31TM. A separate patent (EP 1 296 713 B), which was issued in 2003, covers the second component of the adjuvant, an oligonucleotide (IODN). Both patents together provide broad patent protection for the use of IC31TM as a B and Tcell adjuvant in vaccines.

IC31TM is an adjuvant that induces Tcell and Bcell responses by using a unique synthetic formulation which combines the immunostimulating properties of an antimicrobial peptide, KLK, and an immunostimulatory oligodeoxynucleotide, ODN1a. The two component solution can be simply mixed with antigens; no conjugation is required.

Intercell currently uses IC31(TM) in collaborations with a number of global vaccine companies and biotech companies. These collaborations include the development of a tuberculosis vaccine in Phase I clinical trials, which has been partnered with the Danish Statens Serum Institut, and the development of a therapeutic Hepatitis B vaccine with SciGen Ltd.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance